Simplex Trading
TVTX icon

Simplex Trading’s Travere Therapeutics TVTX Stock Holding History

Simplex Trading’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.76M Buy
59,200
+57,500
+3,382% +$1.72M ﹤0.01% 1935
2025
Q4 		$65K Sell
1,700
-59,100
-97% -$1.92M ﹤0.01% 5411
2025
Q3 		$1.45M Buy
60,800
+15,900
+35% +$299K ﹤0.01% 2652
2025
Q2 		$664K Buy
44,900
+39,100
+674% +$648K ﹤0.01% 3207
2025
Q1 		$103K Sell
5,800
-35,000
-86% -$710K ﹤0.01% 5027
2024
Q4 		$710K Sell
40,800
-6,900
-14% -$122K ﹤0.01% 3193
2024
Q3 		$667K Buy
47,700
+12,500
+36% +$130K ﹤0.01% 3291
2024
Q2 		$289K Buy
35,200
+20,800
+144% +$140K ﹤0.01% 4285
2024
Q1 		$111K Sell
14,400
-3,700
-20% -$31.2K ﹤0.01% 5480
2023
Q4 		$162K Sell
18,100
-41,200
-69% -$300K ﹤0.01% 4884
2023
Q3 		$530K Buy
59,300
+58,200
+5,291% +$821K ﹤0.01% 3336
2023
Q2 		$16K Sell
1,100
-13,600
-93% -$247K ﹤0.01% 7003
2023
Q1 		$330K Buy
14,700
+14,600
+14,600% +$310K ﹤0.01% 3716
2022
Q4 		$2K Buy
+100
New +$2.12K ﹤0.01% 8662
2022
Q3 		– Sell
-200
Closed -$4K – 10920
2022
Q2 		$4K Sell
200
-21,500
-99% -$541K ﹤0.01% 9039
2022
Q1 		$559K Sell
21,700
-4,100
-16% -$109K ﹤0.01% 3706
2021
Q4 		$800K Sell
25,800
-11,100
-30% -$313K ﹤0.01% 3171
2021
Q3 		$575K Buy
36,900
+400
+1% +$7.35K ﹤0.01% 3878
2021
Q2 		$532K Buy
36,500
+36,173
+11,062% +$713K ﹤0.01% 4063
2021
Q1 		$816K Buy
327
+42
+15% +$1.16K ﹤0.01% 2669
2020
Q4 		$776K Buy
285
+276
+3,067% +$6.44K ﹤0.01% 2870
2020
Q3 		$16K Sell
9
-130
-94% -$2.53K ﹤0.01% 6523
2020
Q2 		$283K Sell
139
-31
-18% -$494 ﹤0.01% 3600
2020
Q1 		$248K Buy
170
+163
+2,329% +$2.45K ﹤0.01% 3345
2019
Q4 		$9K Sell
7
-269
-97% -$3.44K ﹤0.01% 6456
2019
Q3 		$319K Buy
276
+241
+689% +$3.98K ﹤0.01% 3110
2019
Q2 		$70K Sell
35
-61
-64% -$1.2K ﹤0.01% 4544
2019
Q1 		$217K Sell
96
-116
-55% -$2.56K ﹤0.01% 3524
2018
Q4 		$479K Buy
212
+34
+19% +$846 ﹤0.01% 2275
2018
Q3 		$511K Buy
+178
New +$5.09K ﹤0.01% 2610
2017
Q2 		– Sell
-68
Closed -$8K – 6817
2017
Q1 		$8K Sell
68
-281
-81% -$5.5K ﹤0.01% 4200
2016
Q4 		$29K Buy
349
+254
+267% +$5.2K ﹤0.01% 2701
2016
Q3 		$9K Buy
95
+22
+30% +$419 ﹤0.01% 3723
2016
Q2 		$8K Sell
73
-30
-29% -$486 ﹤0.01% 3833
2016
Q1 		$16K Sell
103
-83
-45% -$1.26K ﹤0.01% 3014
2015
Q4 		$22K Buy
+186
New +$3.72K ﹤0.01% 2609
2015
Q3 		– Sell
-11
Closed -$2K – 6216
2015
Q2 		$2K Sell
11
-79
-88% -$2.16K ﹤0.01% 4373
2015
Q1 		$1K Buy
+90
New +$1.37K ﹤0.01% 4615

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Simplex Trading's TVTX Position: Q4 2025 in Review

Simplex Trading sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 51,241 shares — an estimated $1.67M sold.

Simplex Trading first reported a position in TVTX in Q4 2014 and held it in 26 quarters. The position peaked at $1.22M in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Simplex Trading reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 51,241 Travere Therapeutics shares in Q4 2025, an estimated $1.67M.
  • Simplex Trading first reported a position in Travere Therapeutics in Q4 2014 and held it in 26 quarters.
  • Simplex Trading's Travere Therapeutics position peaked at $1.22M in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.